Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance

医学 前列腺活检 小心等待 索引(排版) 健康监护 内科学 前列腺癌 环境卫生 癌症 万维网 计算机科学
作者
Christopher P. Filson,Kehao Zhu,Yijian Huang,Yingye Zheng,Lisa F. Newcomb,Sierra Williams,James D. Brooks,Peter R. Carroll,Atreya Dash,William Ellis,Martin Gleave,Michael A. Liss,Frances M. Martin,Jesse K. McKenney,Todd M. Morgan,Andrew A. Wagner,Lori J. Sokoll,Martin G. Sanda,Daniel W. Chan,Daniel W. Lin
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:208 (5): 1037-1045 被引量:1
标识
DOI:10.1097/ju.0000000000002852
摘要

No AccessJournal of UrologyAdult Urology1 Nov 2022Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active SurveillanceThis article is commented on by the following:Editorial CommentEditorial Comment Christopher P. Filson, Kehao Zhu, Yijian Huang, Yingye Zheng, Lisa F. Newcomb, Sierra Williams, James D. Brooks, Peter R. Carroll, Atreya Dash, William J. Ellis, Martin E. Gleave, Michael A. Liss, Frances Martin, Jesse K. McKenney, Todd M. Morgan, Andrew A. Wagner, Lori J. Sokoll, Martin G. Sanda, Daniel W. Chan, and Daniel W. Lin Christopher P. FilsonChristopher P. Filson *Correspondence: Department of Urology, Emory University, School of Medicine, 1365 Clifton Rd. NE, 1st Floor, Building B, Atlanta, Georgia 30322 telephone: 404-778-4898; FAX: 404-778-4006; email: E-mail Address: [email protected] Department of Urology, Emory University School of Medicine, Atlanta, Georgia Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia More articles by this author , Kehao ZhuKehao Zhu Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author , Yijian HuangYijian Huang Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia More articles by this author , Yingye ZhengYingye Zheng Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author , Lisa F. NewcombLisa F. Newcomb https://orcid.org/0000-0003-3505-3754 Department of Urology, University of Washington, Seattle, Washington Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author , Sierra WilliamsSierra Williams Department of Urology, Emory University School of Medicine, Atlanta, Georgia More articles by this author , James D. BrooksJames D. Brooks Department of Urology, Stanford University, Stanford, California More articles by this author , Peter R. CarrollPeter R. Carroll Department of Urology, University of California, San Francisco, California More articles by this author , Atreya DashAtreya Dash VA Puget Sound Health Care Systems, Seattle, Washington More articles by this author , William J. EllisWilliam J. Ellis Department of Urology, University of Washington, Seattle, Washington More articles by this author , Martin E. GleaveMartin E. Gleave Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author , Michael A. LissMichael A. Liss Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas More articles by this author , Frances MartinFrances Martin Department of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia More articles by this author , Jesse K. McKenneyJesse K. McKenney Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio More articles by this author , Todd M. MorganTodd M. Morgan Department of Urology, University of Michigan, Ann Arbor, Michigan More articles by this author , Andrew A. WagnerAndrew A. Wagner Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts More articles by this author , Lori J. SokollLori J. Sokoll Department of Pathology, Urology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author , Martin G. SandaMartin G. Sanda Department of Urology, Emory University School of Medicine, Atlanta, Georgia Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia Co-senior authors. More articles by this author , Daniel W. ChanDaniel W. Chan Department of Pathology, Urology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland Co-senior authors. More articles by this author , and Daniel W. LinDaniel W. Lin Department of Urology, University of Washington, Seattle, Washington Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington Co-senior authors. More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002852AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed whether Prostate Health Index results improve prediction of grade reclassification for men on active surveillance. Methods and Materials: We identified men in Canary Prostate Active Surveillance Study with Grade Group 1 cancer. Outcome was grade reclassification to Grade Group 2+ cancer. We considered decision rules to maximize specificity with sensitivity set at 95%. We derived rules based on clinical data (R1) vs clinical data+Prostate Health Index (R3). We considered an “or”-logic rule combining clinical score and Prostate Health Index (R4), and a “2-step” rule using clinical data followed by risk stratification based on Prostate Health Index (R2). Rules were applied to a validation set, where values of R2-R4 vs R1 for specificity and sensitivity were evaluated. Results: We included 1,532 biopsies (n = 610 discovery; n = 922 validation) among 1,142 men. Grade reclassification was seen in 27% of biopsies (23% discovery, 29% validation). Among the discovery set, at 95% sensitivity, R2 yielded highest specificity at 27% vs 17% for R1. In the validation set, R3 had best performance vs R1 with Δsensitivity = −4% and Δspecificity = +6%. There was slight improvement for R3 vs R1 for confirmatory biopsy (AUC 0.745 vs R1 0.724, ΔAUC 0.021, 95% CI 0.002-0.041) but not for subsequent biopsies (ΔAUC −0.012, 95% CI −0.031-0.006). R3 did not have better discrimination vs R1 among the biopsy cohort overall (ΔAUC 0.007, 95% CI −0.007-0.020). Conclusions: Among active surveillance patients, using Prostate Health Index with clinical data modestly improved prediction of grade reclassification on confirmatory biopsy and did not improve prediction on subsequent biopsies. References 1. . Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018; 199(3):683-690. Link, Google Scholar 2. . Precision medicine in active surveillance for prostate cancer: development of the Canary–Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol. 2015; 68:1083-1088. Google Scholar 3. . A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018; 74(2):197-203. Crossref, Medline, Google Scholar 4. . Predicting biopsy outcomes during active surveillance for prostate cancer: external validation of the Canary prostate active surveillance study risk calculators in five large active surveillance cohorts. Eur Urol. 2019; 76(5):693-702. Google Scholar 5. . Evaluating the four kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer in men in the canary prostate active surveillance study. Eur Urol. 2017; 72(3):448-454. Crossref, Medline, Google Scholar 6. . Canary prostate active surveillance study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010; 75(2):407-413. Google Scholar 7. . Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. JAMA. 2019; 321(7):704-706. Crossref, Medline, Google Scholar 8. . Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urol Oncol. 2021; 39(7):432.e1-432.e10. Google Scholar 9. . Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016; 13(3):151-167. Crossref, Medline, Google Scholar 10. . Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU Int. 2021; 127:96-107. Google Scholar 11. . Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability. JAMA Oncol. 2020; 6(10):e203187. Crossref, Medline, Google Scholar 12. . Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int. 2017; 120(6):793-798. Crossref, Medline, Google Scholar 13. . Association of [−2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol. 2012; 188(4):1131-1136. Link, Google Scholar 14. . Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. BJU Int. 2020; 126(3):373-378. Google Scholar 15. . Increasing utilization of multiparametric magnetic resonance imaging in prostate cancer active surveillance. Urology. 2019; 130:99-105. Google Scholar 16. . Magnetic resonance imaging for the detection of high grade cancer in the canary prostate active surveillance study. J Urol. 2020; 204(4):701-706. Link, Google Scholar 17. . Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol. 2020; 77(3):311-317. Crossref, Medline, Google Scholar Submitted December 10, 2021; accepted June 23, 2022; published July 5, 2022. Support: NIH/NCI Early Detection Research Network, U24 CA115102 (DWC). - PHI assay reagents were provided by Beckman Coulter, Inc. - American Cancer Society MRSG 18-015-01-CPHPS (CPF). - NIH U01 CA224255 (DL). - NIH U01 CA113913 (YH, LN, MGS and DWL). Conflict of Interest: Carroll: Alessa therapeutics Francis Medical Genomic Health/Exact. Ethics Statement: Participants consented to collection of research specimens under institutional regulatory board approval at all participating study sites, and this was approved by the central site institutional regulatory board (IRB No. 7122). © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byHo M, Ross A and Eggener S (2023) Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active SurveillanceJournal of Urology, VOL. 210, NO. 1, (38-45), Online publication date: 1-Jul-2023.Guidotti A, Lombardo R and De Nunzio C (2023) Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.Journal of Urology, VOL. 209, NO. 6, (1107-1108), Online publication date: 1-Jun-2023.Related articlesJournal of Urology10 Aug 2022Editorial CommentJournal of Urology10 Aug 2022Editorial Comment Volume 208Issue 5November 2022Page: 1037-1045Supplementary Materials PEER REVIEW REPORTS Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.Keywordsprostatic neoplasmsbiomarkerswatchful waitingMetricsAuthor Information Christopher P. Filson Department of Urology, Emory University School of Medicine, Atlanta, Georgia Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia *Correspondence: Department of Urology, Emory University, School of Medicine, 1365 Clifton Rd. NE, 1st Floor, Building B, Atlanta, Georgia 30322 telephone: 404-778-4898; FAX: 404-778-4006; email: E-mail Address: [email protected] More articles by this author Kehao Zhu Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author Yijian Huang Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia More articles by this author Yingye Zheng Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author Lisa F. Newcomb Department of Urology, University of Washington, Seattle, Washington Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author Sierra Williams Department of Urology, Emory University School of Medicine, Atlanta, Georgia More articles by this author James D. Brooks Department of Urology, Stanford University, Stanford, California More articles by this author Peter R. Carroll Department of Urology, University of California, San Francisco, California More articles by this author Atreya Dash VA Puget Sound Health Care Systems, Seattle, Washington More articles by this author William J. Ellis Department of Urology, University of Washington, Seattle, Washington More articles by this author Martin E. Gleave Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada More articles by this author Michael A. Liss Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas More articles by this author Frances Martin Department of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia More articles by this author Jesse K. McKenney Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio More articles by this author Todd M. Morgan Department of Urology, University of Michigan, Ann Arbor, Michigan More articles by this author Andrew A. Wagner Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts More articles by this author Lori J. Sokoll Department of Pathology, Urology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland More articles by this author Martin G. Sanda Department of Urology, Emory University School of Medicine, Atlanta, Georgia Winship Cancer Institute, Emory Healthcare, Atlanta, Georgia Co-senior authors. More articles by this author Daniel W. Chan Department of Pathology, Urology, and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland Co-senior authors. More articles by this author Daniel W. Lin Department of Urology, University of Washington, Seattle, Washington Cancer Prevention Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington Co-senior authors. More articles by this author Expand All Submitted December 10, 2021; accepted June 23, 2022; published July 5, 2022. Support: NIH/NCI Early Detection Research Network, U24 CA115102 (DWC). - PHI assay reagents were provided by Beckman Coulter, Inc. - American Cancer Society MRSG 18-015-01-CPHPS (CPF). - NIH U01 CA224255 (DL). - NIH U01 CA113913 (YH, LN, MGS and DWL). Conflict of Interest: Carroll: Alessa therapeutics Francis Medical Genomic Health/Exact. Ethics Statement: Participants consented to collection of research specimens under institutional regulatory board approval at all participating study sites, and this was approved by the central site institutional regulatory board (IRB No. 7122). Advertisement PDF downloadLoading ...
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
xu发布了新的文献求助10
1秒前
害羞的青筠完成签到,获得积分10
1秒前
2秒前
害怕的冷荷完成签到,获得积分10
4秒前
kanwenxian发布了新的文献求助10
4秒前
ajuehdj发布了新的文献求助10
5秒前
like1994发布了新的文献求助10
5秒前
Carly发布了新的文献求助10
5秒前
hoijuon发布了新的文献求助10
6秒前
6秒前
晓婷婷完成签到 ,获得积分10
7秒前
香蕉觅云应助疯狂的炳采纳,获得10
7秒前
7秒前
可爱的函函应助疯狂的炳采纳,获得10
8秒前
8秒前
qqqq完成签到,获得积分10
8秒前
小猴子完成签到,获得积分10
8秒前
Ruby完成签到,获得积分10
11秒前
周周发布了新的文献求助10
11秒前
13秒前
酷波er应助包子采纳,获得30
13秒前
13秒前
idiom完成签到 ,获得积分10
14秒前
YY完成签到,获得积分10
14秒前
科研小菜鸡完成签到,获得积分10
14秒前
X7完成签到,获得积分10
15秒前
Lazarus完成签到,获得积分10
15秒前
15秒前
科研通AI2S应助like1994采纳,获得10
16秒前
折耳根完成签到 ,获得积分10
19秒前
英姑应助周周采纳,获得10
19秒前
19秒前
19秒前
善良的开山完成签到,获得积分10
19秒前
gsh发布了新的文献求助10
20秒前
王赞应助留白采纳,获得10
20秒前
共享精神应助潘多拉采纳,获得10
21秒前
22秒前
爆米花应助mola采纳,获得10
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970004
求助须知:如何正确求助?哪些是违规求助? 3514701
关于积分的说明 11175468
捐赠科研通 3250051
什么是DOI,文献DOI怎么找? 1795187
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804925